The Efficacy and Safety of Anlotinib Combination Therapy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

ABSTRACT: IntroductionAnlotinib, a tyrosine kinase inhibitor, has demonstrated significant anti-tumor activity in hepatocellular carcinoma (HCC); nevertheless, the optimal combination therapy is still contested. Consequently, we synthesized the efficacy and safety of anlotinib in combination therapy for advanced HCC via meta-analysis, offering more extensive data for clinical application.MethodsWe systematically searched PubMed, Embase, Web of Science, and Cochrane Library. The primary efficacy indicators included median overall survival (mOS), median progression-free survival (mPFS), overall response rate (ORR), and disease control rate (DCR). The relevant safety indicators were adverse events (AEs). We conducted a meta-analysis utilizing the STATA 14.0 statistical software.ResultsA total of 14 stu

SUBMITTER: Chen T 

PROVIDER: S-EPMC12536109 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature